CKS is no longer commissioned by the National Institute for Health and Clinical Excellence (NICE). NICE remains committed to providing a replacement service for CKS and is currently reviewing its options. In the meantime, although CKS content is now not being maintained, it still remains relevant and will continue to be made available. CKS content was generated under a programme of topic creation and update. To check if the topic you are viewing is current or out of date, please refer to the topic publication details by clicking on the 'How up-to-date is this topic?' link in the left hand menu on individual topic pages.
Fungal skin infection - scalp - Management
Basis for recommendation
Doses
- The doses of oral antifungal drugs that are recommended are based on the British National Formulary [BNF 57, 2009] and the manufacturer's information for griseofulvin [Chemidex Pharma Ltd., 2005].
- Doses for children have not been included because in most cases specialist advice will be needed. Also, terbinafine is not licensed for this purpose and there is no UK-approved liquid paediatric formulation of griseofulvin.
© NHS Institute for Innovation and Improvement